Houston Researchers Identified Breast Cancer Drug Resistance

Houston Methodist scientists discovered a signaling pathway that limits the effectiveness of T-DXd in metastatic cancer.

Updated on Oct. 1, 2026 in Cancer

Houston Researchers Identified Breast Cancer Drug Resistance

Live Poll

Should medical researchers prioritize testing existing drugs in new combinations to overcome treatment resistance?

Houston Methodist researchers have identified the S100-RAGE signaling pathway as a primary mechanism that allows metastatic breast cancer tumors to resist T-DXd therapy. The study offers a new target to restore drug sensitivity in patients who do not respond to standard treatments.

Why it matters

The findings explain why many HER2-expressing metastatic breast cancers stop responding to T-DXd treatment. By inhibiting the RAGE pathway, clinicians may be able to significantly improve outcomes for patients battling resistant tumors.

Researchers mapped gene and protein activity across 109 metastatic lesions from 47 patients. Increased expression of S100A7, S100A9, and S100P proteins was specifically linked to tumor resistance.

The players

Houston Methodist

This Houston-based hospital system is a leading academic medical center focused on translational research and advanced patient care.

The details

Investigators used spatial transcriptomic and proteomic profiling to visualize how tumor and immune cells interact. By blocking the RAGE pathway, the team successfully restored sensitivity to T-DXd in both laboratory tests and animal models using the inhibitor TTP488.

October 1, 2026: The study findings were published.

The Big Picture

This discovery shifts the trajectory of breast cancer treatment by moving beyond generic drug application to targeting specific protein-driven resistance. It follows the pattern set by the ongoing T-DXd breast cancer treatment protocols, which this study improves by addressing why the therapy sometimes fails.

Patients currently struggling with T-DXd resistance may eventually access new combination therapies involving RAGE inhibitors. This research provides a roadmap for future clinical trials that aim to re-sensitize tumors to existing chemotherapy treatments.

The takeaway

Understanding how tumors evolve to survive chemotherapy is essential for developing personalized oncology strategies. This study highlights the power of spatial modeling to reveal the complex cellular neighborhoods that drive drug resistance.